ANI Pharmaceuticals Inc.

35.39+0.4200+1.20%Vol 96.28K1Y Perf 14.62%
Aug 11th, 2022 16:00 DELAYED
BID14.52 ASK42.88
Open35.33 Previous Close34.97
Pre-Market- After-Market35.39
 - -  - -%
Target Price
40.67 
Analyst Rating
Moderate Buy 2.00
Potential %
14.92 
Finscreener Ranking
★+     43.87
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★★     47.35
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
     34.24
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
34.50 
Earnings Rating
Neutral
Market Cap616.71M 
Earnings Date
8th Aug 2022
Alpha-0.01 Standard Deviation0.12
Beta1.01 

Today's Price Range

34.8235.48

52W Range

22.3160.23

5 Year PE Ratio Range

-410.20213.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
2.22%
1 Month
18.64%
3 Months
41.50%
6 Months
-9.99%
1 Year
14.62%
3 Years
-50.35%
5 Years
-19.59%
10 Years
327.42%

TickerPriceChg.Chg.%
ANIP35.390.42001.20
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
49.20
-29.20
-6.70
-8.50
-27.17
RevenueValueIndustryS&P 500US Markets
177.47M
10.30
1.77
6.72
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.04-0.05-25.00
Q01 2022-0.05-0.27-440.00
Q04 20210.690.38-44.93
Q03 20210.550.8350.91
Q02 20210.510.49-3.92
Q01 20210.580.9258.62
Q04 20200.850.65-23.53
Q03 20200.780.813.85
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.0433.33Positive
9/2022 QR0.3872.73Positive
12/2022 FY0.7427.59Positive
12/2023 FY2.359.81Positive
Next Report Date-
Estimated EPS Next Report-0.04
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume96.28K
Shares Outstanding17.43K
Shares Float9.39M
Trades Count2.26K
Dollar Volume3.39M
Avg. Volume89.15K
Avg. Weekly Volume90.32K
Avg. Monthly Volume76.39K
Avg. Quarterly Volume100.73K

ANI Pharmaceuticals Inc. (NASDAQ: ANIP) stock closed at 35.39 per share at the end of the most recent trading day (a 1.2% change compared to the prior day closing price) with a volume of 96.28K shares and market capitalization of 616.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 338 people. ANI Pharmaceuticals Inc. CEO is Nikhil Lalwani.

The one-year performance of ANI Pharmaceuticals Inc. stock is 14.62%, while year-to-date (YTD) performance is -23.2%. ANIP stock has a five-year performance of -19.59%. Its 52-week range is between 22.31 and 60.2267, which gives ANIP stock a 52-week price range ratio of 34.50%

ANI Pharmaceuticals Inc. currently has a PE ratio of -6.70, a price-to-book (PB) ratio of 1.68, a price-to-sale (PS) ratio of 3.01, a price to cashflow ratio of 100.40, a PEG ratio of 2.32, a ROA of -10.72%, a ROC of -10.27% and a ROE of -24.69%. The company’s profit margin is -27.17%, its EBITDA margin is -6.70%, and its revenue ttm is $177.47 Million , which makes it $10.30 revenue per share.

Of the last four earnings reports from ANI Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. ANI Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ANI Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $40.67, which is +14.92% compared to the current price. The earnings rating for ANI Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ANI Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ANI Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 5.55, ATR14 : 1.63, CCI20 : 109.33, Chaikin Money Flow : 0.08, MACD : 1.29, Money Flow Index : 66.29, ROC : 5.80, RSI : 68.22, STOCH (14,3) : 56.03, STOCH RSI : 0.83, UO : 52.01, Williams %R : -43.97), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ANI Pharmaceuticals Inc. in the last 12-months were: Antonio R. Pera (Buy at a value of $126 794), Chad Gassert (Buy at a value of $275 087), Jeanne Thoma (Buy at a value of $49 820), Muthusamy Shanmugam (Buy at a value of $138 252), Nikhil Lalwani (Buy at a value of $199 997), Patrick D. Walsh (Buy at a value of $138 794)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Moderate Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Hold
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.

CEO: Nikhil Lalwani

Telephone: +1 218 634-3500

Address: 210 Main Street West, Baudette 56623, MN, US

Number of employees: 338

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

76%24%

Bearish Bullish

62%38%

TipRanks News for ANIP

Tue, 09 Aug 2022 12:36 GMT ANI Pharmaceuticals (ANIP) Receives a Buy from Raymond James

- TipRanks. All rights reserved.

News

Stocktwits